Interleukin-based therapy for Cancer: Interleukin-27 (IL-27) suppresses intestinal tumorigenesis via inhibition of IL-17-mediated oncogenic signalling, 11/March/2015, 15.33

Natural product-based therapy for Metastatic tumors: Ursolic acid, a natural compound enriched in apples, decreases the expression of PD-1, a suppressor of activation of T-cells, and activates the immune system via down regulation of its target gene, 11/March/2015, 15.22
March 11, 2015
GOD can extend your life span: Celastrol, an antioxidant compound isolated from the herb Thunder of GOD vine, inhibits senescence and extends life span by down regulating the expression of adenylate cyclase 5 (ADCY5/AC5), 11/March/2014, 15.57
March 11, 2015
Show all

A study from the Laboratory of Gene Regulation and Signal Transduction, Departments of Pharmacology and Pathology, School of Medicine, University of California, San Diego, Gilman Drive, La Jolla, CA 92093-0723, USA shows that “Interleukin-17 receptor a signaling in transformed enterocytes promotes …tumorigenesis.” This study was published in the 14 December  2014 issue of Immunity by Prof Michael Karin, Dr. Wang K, and others.

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Interleukin-based therapy for Cancer: Interleukin-27 (IL-27) suppresses intestinal tumorigenesis via inhibition of IL-17-mediated oncogenic signalling. Thus, pharmacological formulations encompassing ” IL-27 activators” may be used to inhibit intestinal cancer. 

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

To citeBoominathan, Interleukin-based therapy for Cancer: Interleukin-27 (IL-27) suppresses intestinal tumorigenesis via inhibition of IL-17-mediated oncogenic signalling, 11/March/2015,  15.33,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

* Research cooperation

Comments are closed.